O4‐02‐03: Preventing Cognitive Decline in Elderly Demented/depressed Patients and in ApoE4 Mouse As a Model of Human Alzheimer's Disease by Feeding Acetyl‐l‐carnitine and Lipoic Acid

Gjumrakch Aliev,Jiankang Liu,Amanda Lipsitt,Kathryn Fischbach,Mark E. Obrenovich,Bruce N. Ames,Eldar Gasımov,Joseph C. LaManna,Ludis Morales,Valentin Bragin
DOI: https://doi.org/10.1016/j.jalz.2009.05.524
2009-01-01
Alzheimer s & Dementia
Abstract:The E4 isoform of apolipoprotein E (ApoE) is involved in cardiovascular and cerebrovascular disorders and is the most prevalent risk factor for late onset or sporadic AD. ApoE4 transgenic mice are appropriate models for studying the pathogenesis and preclinical treatment of ApoE-related cognitive deficits associated with late onset AD. This study uses the vascular dementia paradigm to analyze the effects of selective mitochondrial antioxidants, acetyl-Carnitine and R-Lipoic acid, and ApoE4 on CBF, neuropathology, brain and vessel ultrastructural abnormalities, and behavior in ApoE4 mice. We have also compared these results with our ongoing clinical study of clinically depressed demented seniors with cardiovascular diseases symptoms. The patients received Alpha-Lipoic Acid, Acetyl-L-Carnitine, Omega-3 and Coenzyme Q-10, along with diet changes, and our recently developed brain activation program. ApoE4 associated factors reduce cerebral blood flow (CBF) gradually to create brain hypoperfusion when compared to wild-type (WT) and the differences in CBF are greatest as animals age from 6-weeks to 12-months. Transmission electron microscopy (TEM) with colloidal gold immunocytochemistry and in situ hybridization using human and mouse DNA probes shows structural damage and mitochondrial DNA overproliferation and/or deletion in young and aged microvessel endothelium of ApoE4 animals, extending to the cytoplasm of perivascular cells, perivascular nerve terminals, hippocampal neurons, and glial cells. Spatial memory and temporal memory tests show a trend in improving cognitive function in ApoE4 mice fed selective mitochondrial antioxidants acetyl-L-Carnitine and R-Lipoic acid. Our clinical results show that patients who receive mitochondrial antioxidants present the maximum significant cognitive improvement at the end of 24 months of the treatment. Further examination of ultrastructural degeneration caused by aging, especially under cardiovascular diseases complication, will likely contribute to our understanding of neurodegenerative etiology and indicates a new avenue of development for novel prophylactic and treatment strategies by ensuing selective mitochondrial antioxidants for the demented patients.
What problem does this paper attempt to address?